• 1
    Silver J, Russell J, Sherwood LM 1985 Regulation by vitamin D metabolites of messenger RNA for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82: 42704273.
  • 2
    Russell JD, Letteiri D, Sherwood LM 1986 Suppression by 1,25-(OH)2D3 of transcription of the parathyroid hormone gene. Endocrinology 119: 28642866.
  • 3
    Cantley LK, Russell J, Lettieri D, Sherwood LM 1985 1,25-dihydroxyvitamin D3 suppresses PTH secretion from bovine parathyroid cells in tissue culture. Endocrinology 117: 21142119.
  • 4
    Chan YL, McKay C, Dye E, Slatopolsky E 1986 The effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int 38: 2732.
  • 5
    Slatopolsky E, Weerts C, Theilan J, Horst R, Harter H, Martin K 1984 Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 21362143.
  • 6
    Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G 1992 Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42: 11911198.
  • 7
    Block GA, Port FK 2002 Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: 12261237.
  • 8
    Hsu Ch 1997 Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29: 641649.
  • 9
    Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H 1995 A new analog of calcitriol, 19-nor-1,25-(OH)2D3, suppresses parathyroid hormone synthesis and secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26: 852860.
  • 10
    Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J 1998 19-nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 14271432.
  • 11
    Frazao JM, Chesney RW, Coburn JW 1998 Intermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 13(Suppl 3): S68S72.
  • 12
    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW 2004 Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877890.
  • 13
    Brown AJ, Ritter CS, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E 1989 The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728732.
  • 14
    Hirata M, Endo K, Katsumata K, Ichikawa F, Kubodera N, Fukagawa M 2002 A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transplant 17(Suppl 10): 4145.
  • 15
    Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y 1998 Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32: 238246.
  • 16
    Slatopolsky E, Cozzolino M, Finch JL 2002 Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats. Kidney Int 62: 12771284.
  • 17
    Foley RN, Parfrey PS, Sarnak MI 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3): S112S119.
  • 18
    US Renal Data System 1999 Annual Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
  • 19
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 14781483.
  • 20
    Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K 2000 Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218223.
  • 21
    Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM 2002 Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695701.
  • 22
    Guerin AP, London GM, Marchais SJ, Metivier F 2002 Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 10141021.
  • 23
    Block GA, Hulbert-Shearon TE, Levin NW 1998 Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607617.
  • 24
    BikleD (ed.) 1983 Assay of Calcium Regulating Hormones. Springer-Verlang, New York, NY, USA.
  • 25
    Reinhardt TA, Horst RL, Littledike ET, Beitz DC 1982 1,25-Dihydroxyvitamin D3 receptor in bovine thymus gland. Biochem Biophys Res Commun 106: 10121018.
  • 26
    Bligh EG, Dyer W 1959 A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911917.
  • 27
    Plum LA, Prahl JM, Xiaohong M, Sicinski RR, Gowlugari S, Clagett-Dame M, DeLuca HF 2004 Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 101: 69006904.
  • 28
    Brown AJ, Ritter CS, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E 1989 The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728732.
  • 29
    Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Nishii Y 1989 Protein-binding properties of 22-oxa-1α,25-dihydroxyvitamin D3, a synthetic analogue of 1α,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 35: 529533.
  • 30
    Dusso A, Gunawardhana S, Negrea L, Finch JL, Lopez-Hilker S, Mori T, Nishii Y, Slatopolsky E, Brown AJ 1991 On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128: 16871692.
  • 31
    Kobayashi T, Tsugawa N, Okano T, Masuda S, Takeuchi A, Kubodera N, Nishii Y 1994 The binding properties, with blood proteins, and tissue distribution of 22-oxa-1,25-dihydroxyvitamin D3, a noncalcemic analogue of 1,25-dihydroxyvitamin D3 in rats. J Nutr Sci Vitaminol (Tokyo) 115: 373380.
  • 32
    Brown AJ, Finch JL, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E 1993 The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133: 27192724.
  • 33
    Yang W, Freedman L 1999 20-Epi analogues of 1,25-dihydroxyvitaminD3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J Biol Chem 274: 1683816845.
  • 34
    Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagiswaw J, Kato S 1999 Selective interaction of vitamin D receptor with transcriptional co activators by a vitamin D analog. Mol J Cell Biol 19: 10491055.
  • 35
    Peleg S, Sastry M, Collins ED, Bishop JE, Norman AW 1995 Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 270: 1055110558.